Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Invested Capital (2017 - 2024)

KalVista Pharmaceuticals' Invested Capital history spans 10 years, with the latest figure at $164.4 million for Q4 2024.

  • For Q4 2024, Invested Capital changed N/A year-over-year to $164.4 million; the TTM value through Dec 2024 reached $164.4 million, changed N/A, while the annual FY2024 figure was $206.6 million, N/A changed from the prior year.
  • Invested Capital for Q4 2024 was $164.4 million at KalVista Pharmaceuticals, up from $134.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $206.6 million in Q2 2024 and bottomed at $58.6 million in Q1 2021.
  • The 4-year median for Invested Capital is $102.1 million (2020), against an average of $116.0 million.
  • The largest annual shift saw Invested Capital crashed 34.74% in 2021 before it rose 24.02% in 2024.
  • A 4-year view of Invested Capital shows it stood at $65.0 million in 2020, then decreased by 9.87% to $58.6 million in 2021, then surged by 95.42% to $114.4 million in 2023, then surged by 43.61% to $164.4 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Invested Capital are $164.4 million (Q4 2024), $134.0 million (Q4 2024), and $172.8 million (Q3 2024).